| Business Summary | | Immtech
International,
Inc.
is
a
biopharmaceutical
company
focused
on
the
discovery,
development,
and
commercialization
of
drugs
for
the
treatment
of
fungal
and
other
infectious
diseases
such
as
tuberculosis,
hepatitis,
pneumonia,
diarrhea
and
AIDS
and
cancer,
through
both
the
Company's
pharmaceutical
program
and
its
biological
program.
The
Company
is
engaged
in
developing
research
programs,
recruiting
scientific
advisors
and
scientists,
negotiating
and
consummating
technology
licensing
agreements,
and
engaging
in
and
sponsoring
drug
research
and
development
activities. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IMMT
is
a
biopharmaceutical
company
focused
on
the
discovery
and
commercialization
of
drugs
for
the
treatment
of
tuberculosis,
fungal
disease,
pneumonia,
diarrhea
and
other
infections.
For
the
three
months
ended
6/30/01,
revenues
rose
from
$136
thousand
to
$1.1
million.
Net
loss
decreased
86%
to
$365
thousand.
Revenues
reflect
increased
collaborative
research
and
development
agreements.
Lower
loss
were
partially
offset
by
higher
legal
and
professional
fees. | More
from
Market Guide: Significant
Developments |
| | | | FY2001
Compensation | | Pay | Exer | |
| T. Stephen Thompson, 54 Pres,
CEO | $150K | -- | Gary Parks, 51 CFO,
Sec., Treasurer | 125K | $38K | Cecilia Chan, 38 Exec.
VP | -- | -- | Dollar
amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|